-
公开(公告)号:US11466076B2
公开(公告)日:2022-10-11
申请号:US16098085
申请日:2017-04-28
申请人: UCB BIOPHARMA SPRL
发明人: Ralph Adams , Sam Philip Heywood
IPC分类号: C07K16/00 , C07K16/18 , C07K14/76 , C07K14/765 , C07K16/06 , A61K39/395 , A61K39/00 , C07K16/46
摘要: The present disclosure relates to a method of modulating the half-life of a binding domain specific to a serum carrier protein by mutating the sequence and a modulated binding domain specific to a serum carrier protein.
-
公开(公告)号:US10457748B2
公开(公告)日:2019-10-29
申请号:US14654240
申请日:2013-12-20
申请人: UCB Biopharma SPRL
摘要: The present disclosure relates to a multi-specific antibody molecule comprising or consisting of three polypeptides: a) a polypeptide chain of formula (I): (Vxx)nVx-Cx-X-V1; and b) a polypeptide chain of formula (II): (Vyy)nVy-Cy c) a polypeptide of formula (III): V2 wherein Vx represents a variable domain, Vxx represents a variable domain, Cx represents a constant region, X represents a linker, V represents a variable domain, Vy represents a variable domain, Vyy represents a variable domain, Cy represents a constant region, V2 represents a variable domain, n independently represents 0 or 1, wherein the polypeptide chain of formula (I) and the polypeptide chain of formula (II) is aligned such that the constant regions Cx and Cy are paired and the variable domains Vx and Vy are paired to form a binding domain and optionally a disulphide bond is present between V and V2, in particular where a disulphide bond is present. The disclosure also extends to pharmaceutical formulation comprising the construct, DNA encoding the constructs and vectors comprising same. The disclosure further extends to a method of expressing the constructs, for example in a host cell and methods for formulating same as a pharmaceutical composition. The disclosure also relates to use of the constructs and formulations in treatment.
-
公开(公告)号:US20160017057A1
公开(公告)日:2016-01-21
申请号:US14654240
申请日:2013-12-20
申请人: UCB BIOPHARMA SPRL
IPC分类号: C07K16/46
CPC分类号: C07K16/468 , C07K16/18 , C07K16/2878 , C07K2317/55 , C07K2317/56 , C07K2317/624 , C07K2317/64 , C07K2317/92 , C07K2319/00
摘要: The present disclosure relates to a multi-specific antibody molecule comprising or consisting of three polypeptides: a) a polypeptide chain of formula (I): (Vxx)nVx-Cx-X—V1; and b) a polypeptide chain of formula (II): (Vyy)nVy-Cy c) a polypeptide of formula (III):V2 wherein Vx represents a variable domain, Vxx represents a variable domain, Cx represents a constant region, X represents a linker, V represents a variable domain, Vy represents a variable domain, Vyy represents a variable domain, Cy represents a constant region, V2 represents a variable domain, n independently represents 0 or 1, wherein the polypeptide chain of formula (I) and the polypeptide chain of formula (II) is aligned such that the constant regions Cx and Cy are paired and the variable domains Vx and Vy are paired to form a binding domain and optionally a disulphide bond is present between V and V2, in particular where a disulphide bond is present. The disclosure also extends to pharmaceutical formulation comprising the construct, DNA encoding the constructs and vectors comprising same. The disclosure further extends to a method of expressing the constructs, for example in a host cell and methods for formulating same as a pharmaceutical composition. The disclosure also relates to use of the constructs and formulations in treatment.
摘要翻译: 本公开涉及包含三种多肽或由以下三种多肽组成的多特异性抗体分子:a)式(I)的多肽链:(Vxx)nVx-Cx-X-V1; b)式(II)的多肽链:(Vyy)nVy-Cy c)式(III)的多肽:V2其中Vx表示可变结构域,Vxx表示可变结构域,Cx表示恒定区,X表示 接头,V表示可变结构域,Vy表示可变结构域,Vyy表示可变结构域,Cy表示恒定区,V2表示可变结构域,n独立地表示0或1,其中式(I)的多肽链和 排列式(II)的多肽链使得恒定区Cx和Cy配对,并且可变结构域Vx和Vy配对形成结合结构域,并且任选地在V和V 2之间存在二硫键,特别是其中 存在二硫键。 本公开还延伸到包含构建体的药物制剂,编码构建体的DNA和包含其的载体。 本公开进一步扩展到表达构建体的方法,例如在宿主细胞中的方法以及用于配制药物组合物的方法。 本公开还涉及在治疗中使用构建体和制剂。
-
公开(公告)号:US20200291104A1
公开(公告)日:2020-09-17
申请号:US16063133
申请日:2016-12-14
申请人: UCB BIOPHARMA SPRL
发明人: Ralph Adams , Pallavi Bhatta , Emma Dave , Sam Philip Heywood , Dave Paul Humphreys , Diane Marshall , Daniel John Lightwood
摘要: The invention relates to antibody molecules having specificity for TNF alpha, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
-
公开(公告)号:US20200055959A1
公开(公告)日:2020-02-20
申请号:US16573893
申请日:2019-09-17
申请人: UCB Biopharma SPRL
摘要: The present disclosure relates to a multi-specific antibody molecule comprising or consisting of three polypeptides: a) a polypeptide chain of formula (I):(Vxx)nVx-Cx-X-V1; and b) a polypeptide chain of formula (II): (Vyy)nVy-Cy c) a polypeptide of formula (III):V2 wherein Vx represents a variable domain, Vxx represents a variable domain, Cx represents a constant region, X represents a linker, V represents a variable domain, Vy represents a variable domain, Vyy represents a variable domain, Cy represents a constant region, V2 represents a variable domain, nindependently represents 0 or 1, wherein the polypeptide chain of formula (I) and the polypeptide chain of formula (II) is aligned such that the constant regions Cx and Cy are paired and the variable domains Vx and Vy are paired to form a binding domain and optionally a disulphide bond is present between V1 and V2, in particular where a disulphide bond is present. The disclosure also extends to pharmaceutical formulation comprising the construct, DNA encoding the constructs and vectors comprising same. The disclosure further extends to a method of expressing the constructs, for example in a host cell and methods for formulating same as a pharmaceutical composition. The disclosure also relates to use of the constructs and formulations in treatment.
-
公开(公告)号:US09873735B2
公开(公告)日:2018-01-23
申请号:US14697142
申请日:2015-04-27
申请人: UCB Biopharma SPRL
IPC分类号: A61K39/395 , C07K16/18 , C07K16/28 , A61K39/00
CPC分类号: C07K16/18 , A61K39/3955 , A61K2039/505 , C07K16/2866 , C07K16/2878 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2317/624 , C07K2317/64 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
-
公开(公告)号:US20160031974A1
公开(公告)日:2016-02-04
申请号:US14697142
申请日:2015-04-27
申请人: UCB Biopharma SPRL
IPC分类号: C07K16/18 , A61K39/395 , C07K16/28
CPC分类号: C07K16/18 , A61K39/3955 , A61K2039/505 , C07K16/2866 , C07K16/2878 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2317/624 , C07K2317/64 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
摘要翻译: 本发明涉及对人OX40的抗原决定簇具有特异性的抗体分子,抗体分子的治疗用途以及产生所述抗体分子的方法。
-
公开(公告)号:US10829565B2
公开(公告)日:2020-11-10
申请号:US15568018
申请日:2016-04-22
申请人: UCB BIOPHARMA SPRL
摘要: The present invention provides method for increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises a) a thermal conversion step of holding the composition comprising the antibody molecule at a temperature in the range 30 to 60° C. for a period of at least 1 hour, wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.
-
公开(公告)号:US09803004B2
公开(公告)日:2017-10-31
申请号:US14356181
申请日:2012-11-09
申请人: UCB Biopharma SPRL
CPC分类号: C07K16/18 , C07K16/2878 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/624 , C07K2317/92
摘要: A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 or SEQ ID NO:2 and/or comprising a light chain variable domain having the sequence given in SEQ ID NO:3 or SEQ ID NO:4, in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 1 and SEQ ID NO:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 2 and SEQ ID NO:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments, vectors comprising same and host cells capable of expressing the polynucleotides. The disclosure further includes pharmaceutical compositions comprising the antibodies or fragments and therapeutic used of any one of the same.
-
公开(公告)号:US10828366B2
公开(公告)日:2020-11-10
申请号:US15566307
申请日:2016-04-22
申请人: UCB BIOPHARMA SPRL
IPC分类号: C07K1/22 , C07K16/28 , C07K16/46 , C07K16/00 , A61K39/395 , C07K1/113 , C07K16/18 , C07C323/12 , C07C323/25 , C07K5/12
摘要: The present invention provides method of increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises: a) a conversion step of treating the composition with a denaturant selected from urea and/or Guanidine hydrochloride; b) wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.
-
-
-
-
-
-
-
-
-